Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.09
+0.51006.73%
Post-market: 8.110.0209+0.26%19:58 EDT
Volume:7.21M
Turnover:58.70M
Market Cap:837.99M
PE:-1.55
High:8.40
Open:7.79
Low:7.75
Close:7.58
Loading ...

Intellia Therapeutics Inc - Expects to Complete Enrollment in Phase 3 Study by H2 2025

THOMSON REUTERS
·
22 Jan

Intellia Therapeutics Inc: Expects to Submit a Bla in 2026 to Support Plans for a U.S. Launch in 2027

THOMSON REUTERS
·
22 Jan

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

GlobeNewswire
·
22 Jan

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Zacks
·
18 Jan

CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?

Zacks
·
17 Jan

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Zacks
·
17 Jan

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), CareDx (CDNA) and Intellia Therapeutics (NTLA)

TIPRANKS
·
14 Jan

Intellia ATTR, HAE studies progressing as planned, says JPMorgan

TIPRANKS
·
14 Jan

Intellia Therapeutics: Strategic Initiatives and Clinical Progress Justify Buy Rating

TIPRANKS
·
14 Jan

Intellia Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
14 Jan

Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
13 Jan

U.S. RESEARCH ROUNDUP- Constellation Brands, Merck, WD-40

Reuters
·
13 Jan

Intellia Therapeutics’ Strategic Reorganization and Promising Clinical Progress Justify Buy Rating

TIPRANKS
·
13 Jan

Intellia Therapeutics Inc : Jefferies Cuts Target Price to $86 From $128

THOMSON REUTERS
·
13 Jan

Intellia Therapeutics Inc : Oppenheimer Cuts Target Price to $40 From $60

THOMSON REUTERS
·
13 Jan

Strategic Focus and Financial Resilience: Terence Flynn’s Positive Outlook on Intellia Therapeutics

TIPRANKS
·
11 Jan

Analysts’ Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)

TIPRANKS
·
11 Jan

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

TipRanks
·
11 Jan

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

TIPRANKS
·
10 Jan

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Zacks
·
10 Jan